Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 2, 2021

View Archived Issues

Targeting the NOX1-IL-6-secretory phenotype proinflammatory signaling axis can ease cell senescence

Engineered Salmonella for intracellular delivery of protein drugs to solid tumors

Researchers recapitulate anti-NMDA receptor encephalitis in zebrafish

FD-223, a novel PI3Kdelta inhibitor with potent activity in models of AML

Ndufv2 as a sex-specific genetic factor influencing mitochondrial functions

Almirall patents new TYK2 inhibitors

GWAS meta-analysis identifies genetic variants linked to vertigo

Mitobridge discloses new CD38 inhibitors

Disarm Therapeutics discloses SARM1 inhibitors

Cocrystal Pharma presents new antiviral compounds

iTeos Belgium describes new ENT1 inhibitors

RM-1490, a novel MOR agonist as maintenance therapeutic in opioid use disorder

Imugene and Eureka collaborate to evaluate oncolytic virus and T-cell therapy for solid tumors

APTA-1 shows promise in coronavirus-induced acute lung injury model

Mosaic ImmunoEngineering presents structural details on cowpea mosaic virus

Studies link GRP78 to severe COVID-19 in older and obese diabetic patients

High blood LPE(20:4) levels tied to migraine

Moderna and Metagenomi collaborate to advance in vivo gene editing therapeutics

Studies show that psoriasis is more than skin-deep

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...